Research progress of regorafenib in the treatment of colorectal cancer

Colorectal cancer (CRC) is a common malignant tumor of digestive tract with an increasing incidence and mortality worldwide, and most patients have lost the opportunity of surgical treatment once diagnosed. With the continuous development of precision targeted therapy, anti-angiogenesis targeted drugs have achieved good therapeutic effect in the treatment of advanced CRC. Regorafenib is a multi-target oral tyrosine kinase inhibitor, which can improve the tumor immune microenvironment by regulating tumor-associated macrophage, vascular endothelial growth factor receptor, and has a synergistic effect with immunotherapy. This article reviews the progress of basic and clinical research on regorafenib in the field of CRC.